{
  "id": 3552261,
  "title": "Phase-resolved transcriptomic bottlenecks in peptide cancer vaccine response",
  "url": "https://urgent.news/2026/08/26/phase-resolved-transcriptomic-bottlenecks-in-peptide-cancer-vaccine",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.21.746349v1?rss=1"
  },
  "original_language": "en",
  "account": "Peptide cancer vaccines have shown promise in eliciting antigen-specific immunity, yet their ability to translate into long-lasting tumor control remains limited. To better understand the underlying mechanisms, researchers conducted a comprehensive analysis of transcriptomic profiles across three public human peptide-vaccine cohorts: C1/GSE278476, C2/GSE85698, and C3/GSE53922.\n\nThe study focused on specific gene modules and utilized mean standardized scores to assess their impact on vaccine response. In cohort C1, baseline immune-readiness demonstrated a favorable pattern, with a positive association (beta=0.301, p=0.0072) and longer survival in cohort C3 (HR=0.662, 95% CI 0.532-0.823, p=0.000206). However, baseline erythroid/inflammatory drag exhibited an inverse relationship in C1 (beta=-0.258, p=0.031), which was linked to inferior survival in C3 (HR=1.390, 95% CI 1.181-1.636, p=0.0000755).\n\nMoving on to cohort C2, the analysis revealed lower tolerogenic/myeloid dendritic-cell product-state expression in strong ELISpot responders (8/19 focused genes, q-values). These findings suggest that the transcriptomic landscape plays a crucial role in determining the effectiveness of peptide cancer vaccines and could inform future strategies to improve vaccine response and patient outcomes.",
  "summary": "Background: Peptide cancer vaccines can elicit antigen-specific immunity, but peripheral immunogenicity often does not translate into durable tumor control. Methods: We analyzed transcriptomic profiles across three public human peptide-vaccine cohorts: C1/GSE278476, a MUC1 plus Poly-ICLC PBMC RNA-seq cohort with ordered anti-MUC1 IgG response classes; C2/GSE85698, manufactured dendritic-cell…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}